Robin & The Group,
I'm a scientist with 7 years experience working in the pharmaceutical industry who is new to this group but have been tracking PRLN for over a year now. First, I'd like to say that I
have recently increased my postion in PRLN, having purchased another 4,000 shares. I believe that this is still a very high risk stock but one with extraordinary potential. Anyone familiar with current anti-viral drugs (I've worked on HIV, Influenza, Huma Papillomavirus and Hepatitis B & C)knows how expensive and often toxic current treatments can be. Hence, any product that is both safe and inexpensive, such as AndroVir, is bound to be a sure hit, especially with AIDS patients. The only conclusion I reserve judgement on is it's efficacy. Although the initial clinical trials suggested a high level of effectiveness, the number of patients enrolled in this study is not statistically significant. You would need to conduct a clinical trial on 1,000's of AIDS patients before you could come to a conclusion on this. This is obviously why PRLN has choosen the dietary supplement route. To conduct clinical studies extensive enough to market AndroVir as a prescription drug would require big funding from a big drug company. In the end, PRLN would have to sign over so much of it's rights to such a pharmaceutical partner that they would stand to gain little more than a licensing fee. None the less, I believe the product will probably help enough people to give it a shot at establishing significant market penetration. After all, if yo had AIDS, what would you rather do? Take drugs who's side effects are almost as bad as the disease itself and cost $10,000's per year or a herbal based remedy that costs less than $1,000 per year and is safe?
I also feel that PRLN has outstanding potential in terms of bringing other products to the market in the future. The only wild card here is how aggresively will their marketing/manufacturing/distribution partners be with AndroVir, AndroCar, or future products? If they sit on their hands, the ship could very well sink. Also, exactly what is the financial agreement between PRLN and their partner (I forget their name)? How big a piece of the pie do each of them get? If anyone knows an answer to this, I'd appreciate it if you'd let me know. As for todays market weakness, I wouldn't worry about it. Biotech's in general are still off because the money is still flowing into large caps. But- that tide is due to turn soon.
Hank |
